Iterum Therapeutics Plc (ITRM)

$0.03 -0.04 (-57.39%)
Market Cap 1.60M
Revenue (ttm) 0.00
Net Income (ttm) -24.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -2.88
Volume 65,735,500
Avg Vol 19,797,338
Day's Range N/A - N/A
Shares Out 53.29M
Stochastic %K 2%
Beta 2.96
Analysts Hold
Price Target $9.00

Company Profile

Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel...

Industry: Biotechnology
Sector: Healthcare
Phone: 353 1 903 8354
Address:
3 Dublin Landings, North Wall Quay, Dublin, Ireland
YakoCapital
YakoCapital Jun. 24 at 12:52 PM
$ITRM Delisting Determination, The Nasdaq Stock Market, LLC, May 11, 2026 Iterum Therapeutics plc The Nasdaq Stock Market LLC (the Exchange) has determined to remove from listing the ordinary shares of Iterum Therapeutics plc effective at the opening of the trading session on July 6, 2026. Based on review of information provided by the Company, Nasdaq Staff determined that the Company no longer qualified for listing on the Exchange pursuant to Listing Rule 5550(a)(2). The Company was notified of the Staff determination on February 24, 2026. On March 3, 2026 the Company exercised its right to appeal the Staff determination to the Listing Qualifications Hearings Panel (Panel) pursuant to Listing Rule 5815. On March 27, 2026, the Company withdrew its appeal of Nasdaq Staff's Delist Determination Letter. On March 30, 2026 Nasdaq issued a letter informing the Company that its ordinary shares would be suspended from the Exchange. The Company ordinary shares were suspended on April 1, 2026.
0 · Reply
YakoCapital
YakoCapital Jun. 24 at 11:16 AM
$ITRM Based on my research, SEC form 25 is usually released/come around the same time when the acquisition completion news is sent out. I am just saying....
0 · Reply
Biorocksme
Biorocksme Jun. 24 at 10:48 AM
$ITRM Following the Irish High Court's full winding-up order, the Bermuda subsidiary also moved into compulsory liquidation under Teneo’s regional specialists (Michael Morrison and Charles Thresh). The Bermuda liquidators explicitly certified that there are insufficient assets to cover the debt layers. This reinforces that Orlynvah’s intellectual property and remaining physical inventory are being processed strictly as distressed collateral to satisfy senior secured and creditor claims, rather than being maintained as a going concern.
2 · Reply
buyitcheapest
buyitcheapest Jun. 24 at 1:50 AM
$ITRM No worries, we will all end up with the same results. Your holdings have the same legal standing as theirs regardless of what anyone does. They just want to make people aware and have influence on the outcome.
0 · Reply
Amb8675309
Amb8675309 Jun. 24 at 1:45 AM
$ITRM anyone that thinks just because Teneo likes to operate on the up and up and same with ITRM‘s lawyers,ALGoodbody, don’t think for a second that if it’s totally a bad outcome for us, but technically legal, they will do anything they can to Hoover up any money that’s left over after creditors are paid off. If you believe, as I do, that Fishman made the decision to do a liquidation well over a year ago, knowing that the stock price would go to zero and everybody that was sitting there, as shareholders,hoping and believing the launch was for real, don’t think for a minute that if there isn’t a legal way to come up with BS last minute creditor invoices, that they won’t do it. As long as they can legally defend it, they will do it. This guy was never about the shareholders. He just SAID he was. This guy was always about himself.
2 · Reply
Biorocksme
Biorocksme Jun. 24 at 12:32 AM
$ITRM shitoutluckMikey is not proud of this
2 · Reply
Jamesohara
Jamesohara Jun. 23 at 8:39 PM
$ITRM same's pretty selfish.If I only do one's holding three hundred thousand shares , if you ain't done it forever dollar a day , then you were piece of s***
3 · Reply
DollerADay
DollerADay Jun. 23 at 7:13 PM
$ITRM This is essentially the final paperwork for a process that already happened. Iterum’s shares were removed from Nasdaq months ago when the company entered liquidation. Form 25 is the SEC mechanism Nasdaq uses to formally terminate the listing registration. Means nothing
1 · Reply
1stPlace
1stPlace Jun. 23 at 7:05 PM
$ITRM https://ir.iterumtx.com/sec-filings#document-1068-0001354457-26-000607
2 · Reply
Amb8675309
Amb8675309 Jun. 23 at 5:34 PM
$ITRM for the person that thinks you don’t have to file a 13D, because it’s in liquidation- guys please check your statements first before you post:
3 · Reply
Latest News on ITRM
No data available.
YakoCapital
YakoCapital Jun. 24 at 12:52 PM
$ITRM Delisting Determination, The Nasdaq Stock Market, LLC, May 11, 2026 Iterum Therapeutics plc The Nasdaq Stock Market LLC (the Exchange) has determined to remove from listing the ordinary shares of Iterum Therapeutics plc effective at the opening of the trading session on July 6, 2026. Based on review of information provided by the Company, Nasdaq Staff determined that the Company no longer qualified for listing on the Exchange pursuant to Listing Rule 5550(a)(2). The Company was notified of the Staff determination on February 24, 2026. On March 3, 2026 the Company exercised its right to appeal the Staff determination to the Listing Qualifications Hearings Panel (Panel) pursuant to Listing Rule 5815. On March 27, 2026, the Company withdrew its appeal of Nasdaq Staff's Delist Determination Letter. On March 30, 2026 Nasdaq issued a letter informing the Company that its ordinary shares would be suspended from the Exchange. The Company ordinary shares were suspended on April 1, 2026.
0 · Reply
YakoCapital
YakoCapital Jun. 24 at 11:16 AM
$ITRM Based on my research, SEC form 25 is usually released/come around the same time when the acquisition completion news is sent out. I am just saying....
0 · Reply
Biorocksme
Biorocksme Jun. 24 at 10:48 AM
$ITRM Following the Irish High Court's full winding-up order, the Bermuda subsidiary also moved into compulsory liquidation under Teneo’s regional specialists (Michael Morrison and Charles Thresh). The Bermuda liquidators explicitly certified that there are insufficient assets to cover the debt layers. This reinforces that Orlynvah’s intellectual property and remaining physical inventory are being processed strictly as distressed collateral to satisfy senior secured and creditor claims, rather than being maintained as a going concern.
2 · Reply
buyitcheapest
buyitcheapest Jun. 24 at 1:50 AM
$ITRM No worries, we will all end up with the same results. Your holdings have the same legal standing as theirs regardless of what anyone does. They just want to make people aware and have influence on the outcome.
0 · Reply
Amb8675309
Amb8675309 Jun. 24 at 1:45 AM
$ITRM anyone that thinks just because Teneo likes to operate on the up and up and same with ITRM‘s lawyers,ALGoodbody, don’t think for a second that if it’s totally a bad outcome for us, but technically legal, they will do anything they can to Hoover up any money that’s left over after creditors are paid off. If you believe, as I do, that Fishman made the decision to do a liquidation well over a year ago, knowing that the stock price would go to zero and everybody that was sitting there, as shareholders,hoping and believing the launch was for real, don’t think for a minute that if there isn’t a legal way to come up with BS last minute creditor invoices, that they won’t do it. As long as they can legally defend it, they will do it. This guy was never about the shareholders. He just SAID he was. This guy was always about himself.
2 · Reply
Biorocksme
Biorocksme Jun. 24 at 12:32 AM
$ITRM shitoutluckMikey is not proud of this
2 · Reply
Jamesohara
Jamesohara Jun. 23 at 8:39 PM
$ITRM same's pretty selfish.If I only do one's holding three hundred thousand shares , if you ain't done it forever dollar a day , then you were piece of s***
3 · Reply
DollerADay
DollerADay Jun. 23 at 7:13 PM
$ITRM This is essentially the final paperwork for a process that already happened. Iterum’s shares were removed from Nasdaq months ago when the company entered liquidation. Form 25 is the SEC mechanism Nasdaq uses to formally terminate the listing registration. Means nothing
1 · Reply
1stPlace
1stPlace Jun. 23 at 7:05 PM
$ITRM https://ir.iterumtx.com/sec-filings#document-1068-0001354457-26-000607
2 · Reply
Amb8675309
Amb8675309 Jun. 23 at 5:34 PM
$ITRM for the person that thinks you don’t have to file a 13D, because it’s in liquidation- guys please check your statements first before you post:
3 · Reply
DollerADay
DollerADay Jun. 23 at 5:02 PM
$ITRM Anyone that has 300K+ shares that want to be included in the action group please DM me. You will be part of all comms going forward and document reviews. Cheers
6 · Reply
Amb8675309
Amb8675309 Jun. 23 at 3:47 PM
$ITRM @XJCX when he announced liquidation I was surprised- but then instantly thinking: he’s doing this for a reason. Why? He put millions into this company as seed money. He’d lose that, ie his shares go to zero, and no CoC bonus because company wasn’t being “sold.”- but… dollar did some digging- his options vest upon liquidation. As a FORMER CEO, now he’s free to buy shares at $.03/share. As long as he doesn’t buy more than 4.99%, then no 13D required. Explains why he dodged my direct questions of “buy some shares Corey! It’s embarrassing how few shares you and rest of leadership team have”… why buy any shares at $.50/share if you know you’re headed to liquidation? Plenty of time to buy at $.03/share once liquidation announced; or… to have your unvested options vest, and get those shares for free….
2 · Reply
Amb8675309
Amb8675309 Jun. 23 at 3:36 PM
$ITRM I’ve realized for several months- CF decided on liquidation sometime right after he was lowballed. That’s why he wasted 10 months NOT starting a launch. Asking PFE for a 3 year extension in early spring but not getting any money from them was like turning right onto a road marked “No Outlet” it made no sense. Ask for 3 years, then do a PIPE(and go to extreme lengths to hide identity of PIPE buyer +give them a $.30/share discount), and then start a launch HALF WAY THRU Q3, so initial Qly numbers would be cut in half, hire Coyne but only show she got options(so she got no salary? Did her options instantly vest if ITRM goes into liquidation😎)? Ask for dilution from shareholders who had ALREADY sued him? Ask again for a different amount a few months later-with no launch #s? All of it for SHOW- legally he looks like he TRIED. It was OUR fault. It was evil big pharma fault for lowballing… Now: TENEO will tamp down RLN payout, extract higher value for IP. All we had to do was hang on
0 · Reply
XJCX
XJCX Jun. 23 at 7:25 AM
$ITRM If I compare my impression from March with the one I have now, the difference is that in March I saw it as just another pharmaceutical liquidation (a failed asset and lack of liquidity). Today, I see an extraordinarily orderly liquidation centered around an asset that continues to show signs of commercial life and strategic relevance months after the insolvency began. This doesn’t guarantee a favorable outcome for the shareholders, but it does make the case much less typical than it seemed when Teneo first stepped in. We’ll see if the process is being handled cleanly and whether the creditors aren’t inflating their claims. We have a guardian on our side: a judge and a company (Teneo) with a reputation to protect.
5 · Reply
XJCX
XJCX Jun. 23 at 7:19 AM
$ITRM Orlynvah’s reimbursement and coverage infrastructure has kept evolving even after the liquidation process began.
0 · Reply
Aircastles
Aircastles Jun. 23 at 1:15 AM
$ITRM some more for this month…& it’s not even the full list, it’s clear that Orlynvah still lives on *Wisconsin Medicaid / ForwardHealth – Prior Authorization / Preferred Drug List (PA/PDL) pathway for Blujepa and Orlynvah * Kaiser Permanente Georgia 2026 Four-Tier Formulary – Orlynvah listed * Kaiser Permanente California (KPIC POS) 2026 Formulary with Specialty Tier – Orlynvah listed * Blue Care Network / BCBS Michigan HMO Custom Drug List – Orlynvah listed * Blue Cross Blue Shield Michigan PPO Drug List – Orlynvah listed * Blue Cross Blue Shield Michigan HMO Custom Drug List – Orlynvah listed * TRICARE / Department of Defense UF-BAP Review Process (to review for this week)
1 · Reply
Toptopy
Toptopy Jun. 23 at 12:45 AM
$ITRM For this month
1 · Reply
StonkZombie
StonkZombie Jun. 22 at 9:49 PM
$ITRM Keep preaching evangelistic drivel Forget about hypotheticals. If this was worth 100's of millions of dollars, why didn't any 100's of millions of dollars deal go through? Does anyone REALLY think a potential buyer would have let a deal fall through because Fishman ran out of, what, a couple of months of runway? 😆 They would have found a way. Given Iterum a bridge loan Now the 500-pound gorilla in the room. By all accounts Iterum had runway "into the second quarter of 2026". So why did he file for a wrap up at the end of the first quarter if all Fishman needed was a couple more months to close a deal? Because there was no deal. To this day nobody, not a single soul can prove in any way there WAS a deal. Or "multiple deals". It. Doesn't. Make. Sense. Unless it was just a scam being run under the pretense of a legitimate drug. The senior management were the only ones that ever got paid handsomely. "Put no faith in phrase-mongering, it is better to see who stands to gain!" -VL 💸
2 · Reply
Steloco1
Steloco1 Jun. 22 at 9:13 PM
$ITRM For the record, I said this a year back. The intrinsic value of Orly is at least 800 mil. Who will step up ?
2 · Reply
Steloco1
Steloco1 Jun. 22 at 8:38 PM
$ITRM that's why I'm l/expecting for $200 to 400mil for Orly. Minimum..
1 · Reply
DollerADay
DollerADay Jun. 22 at 8:34 PM
$ITRM For those of you who aren’t aware of the specifics of the Qpex Shionogi deal. They bought a phase 1 drug that best case won’t reach patients until 2030. It’s a cUTI drug that is very complimentary with Orlynvah. If Shionogi was willing to spend $140 million on an unapproved future antibiotic platform, why would an FDA-approved oral antibiotic with commercial infrastructure, payer access, and immediate revenue potential be worth less? Not too mention the vast optionality and BARDA/Subsidies safety net…
0 · Reply
Robinhunt28
Robinhunt28 Jun. 22 at 8:20 PM
$ITRM Finally some good news https://www.statnews.com/2026/06/22/pharma-biotech-ma-boom-2026-deals-total-123-billion/ Pharma Gients on Shopping... so far 123 Billion delaw announced and hoping for for....
2 · Reply